Role of DNA repair defects in predicting immunotherapy response

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Defects in DNA damage response (DDR) are prevalent in cancer, influencing tumor growth and treatment outcomes.
• Immune checkpoint blockade (ICB) shows promise for mismatch repair-deficient tumors, prompting investigation into other DDR defects' role in ICB sensitivity.

Purpose of the Study:

• To explore the mechanisms linking DDR defects and ICB response.
• To describe the clinical activity of ICB in patients with DDR-defective tumors.
• To identify potential biomarkers within DDR pathways for predicting ICB therapy response.

Main Methods:

• Review of recent studies on DDR defects and ICB therapy.
• Analysis of clinical data on ICB efficacy in DDR-defective tumors.
• Exploration of molecular mechanisms connecting DDR and immune response.

Main Results:

• Biomarkers in DDR pathways are emerging as potential predictors for ICB therapy selection.
• The clinical activity of ICB in DDR-defective tumors requires further comprehensive description.

Conclusions:

• Understanding the relationship between DDR deficiency and ICB response is crucial for optimizing immunotherapy.
• DDR pathway biomarkers may guide patient selection for ICB therapy, enhancing treatment efficacy.